Comparative Pharmacology
Head-to-head clinical analysis: NOVOLIN N versus NOVOLIN R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLIN N versus NOVOLIN R.
NOVOLIN N vs NOVOLIN R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog that lowers blood glucose by promoting cellular uptake of glucose, inhibiting hepatic glucose production, and stimulating lipogenesis and protein synthesis.
Regular insulin lowers blood glucose by promoting peripheral glucose uptake, especially in skeletal muscle and adipose tissue, and by inhibiting hepatic glucose production. It binds to insulin receptors on cell membranes, activating tyrosine kinase activity and downstream signaling pathways that regulate glucose transport and metabolism.
Subcutaneous injection. Typical starting dose for type 1 diabetes: 0.5-1.0 units/kg/day divided into 2 doses (morning and evening). For type 2 diabetes: 10 units once or twice daily, adjusted based on blood glucose levels.
Subcutaneous: 0.5-1 unit/kg/day divided into 2-3 doses; intravenous: continuous infusion starting at 0.05-0.1 units/kg/hr adjusted based on blood glucose.
None Documented
None Documented
10-12 hours for intermediate-acting insulin, with a peak effect at 2-8 hours and duration up to 24 hours. Terminal half-life in subcutaneous depot is 4-6 hours.
Intravenous: 5-10 minutes (short due to rapid distribution and degradation). Subcutaneous: 1-2 hours (terminal half-life after absorption).
Renal: 30-80% of dose excreted as unchanged insulin and metabolites. Biliary/fecal: negligible (<1%).
Renal (tubular reabsorption and metabolism). Approximately 50-80% of insulin is degraded in the liver and kidneys; the remainder is excreted in urine as metabolites and intact hormone (<1%).
Category C
Category C
Insulin
Insulin